UY34278A - Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades - Google Patents

Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades

Info

Publication number
UY34278A
UY34278A UY0001034278A UY34278A UY34278A UY 34278 A UY34278 A UY 34278A UY 0001034278 A UY0001034278 A UY 0001034278A UY 34278 A UY34278 A UY 34278A UY 34278 A UY34278 A UY 34278A
Authority
UY
Uruguay
Prior art keywords
noxedine
oxazine
diseases
derivatives
treatment
Prior art date
Application number
UY0001034278A
Other languages
English (en)
Inventor
Rainer Martin Lueoend
Machauer Rainer
Rueeger Heinrich
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018309&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34278(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY34278A publication Critical patent/UY34278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La invención se relaciona con derivados novedosos de oxazina de la fórmula (I), y sales farmacéuicamente aceptables de los mismos, en donde todas las variables son como se definen en la especificación, composiciones farmacéuticas de las mismas, combinaciones de las mismas, y su uso como medicamentos, particularmente para el tratamiento de la Enfermedad de Alzheimer o diabetes a través de la inhibición de la BACE- 1 o la BACE- 2.
UY0001034278A 2011-08-25 2012-08-20 Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades UY34278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527172P 2011-08-25 2011-08-25
US201261665395P 2012-06-28 2012-06-28

Publications (1)

Publication Number Publication Date
UY34278A true UY34278A (es) 2013-04-05

Family

ID=47018309

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034278A UY34278A (es) 2011-08-25 2012-08-20 Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades

Country Status (28)

Country Link
US (2) US9163011B2 (es)
EP (2) EP2748162B1 (es)
JP (1) JP5816369B2 (es)
KR (1) KR101601571B1 (es)
CN (1) CN103906748B (es)
AP (1) AP2014007507A0 (es)
AR (1) AR087668A1 (es)
AU (1) AU2012298177B2 (es)
BR (1) BR112014004131A2 (es)
CA (1) CA2845093A1 (es)
CL (1) CL2014000458A1 (es)
CO (1) CO6890097A2 (es)
CR (1) CR20140084A (es)
EA (1) EA024580B1 (es)
ES (2) ES2638832T3 (es)
GT (1) GT201400031A (es)
HK (1) HK1195903A1 (es)
IL (1) IL230975A0 (es)
MA (1) MA35356B1 (es)
MX (1) MX339303B (es)
PE (1) PE20141540A1 (es)
PL (1) PL2748162T3 (es)
SG (1) SG2014012108A (es)
TN (1) TN2014000062A1 (es)
TW (1) TW201313706A (es)
UY (1) UY34278A (es)
WO (1) WO2013027188A1 (es)
ZA (1) ZA201401139B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119161B (zh) 2008-06-13 2015-07-08 盐野义制药株式会社 具有β分泌酶抑制作用的含硫杂环衍生物
UA110467C2 (uk) 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
PL2663561T3 (pl) 2011-01-13 2016-10-31 Nowe pochodne heterocykliczne i ich zastosowanie w leczeniu zaburzeń neurologicznych
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
AU2014223334C1 (en) * 2013-03-01 2018-10-18 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
CA2903215C (en) 2013-03-08 2021-07-20 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP2984086A1 (en) * 2013-04-11 2016-02-17 F. Hoffmann-La Roche AG Bace1 inhibitors
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Ｂａｃｅ抑制劑
EP3107897A1 (en) 2014-02-19 2016-12-28 H. Lundbeck A/S 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
EP3177618A1 (en) 2014-08-08 2017-06-14 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
HUE060353T2 (hu) * 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
MX2018001699A (es) 2015-08-12 2018-05-07 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1.
US20190055231A1 (en) * 2016-03-01 2019-02-21 Hoffmann-La Roche Inc. Bace1 inhibitors
CA3047290A1 (en) 2016-12-15 2018-06-21 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
ES2910367T3 (es) 2016-12-15 2022-05-12 Amgen Inc Derivados de tiazina y oxazina bicíclicos como inhibidores de beta-secretasa y métodos de uso
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法
CA3047287A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
AU2017376441B2 (en) * 2016-12-15 2021-10-14 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
MX2020011382A (es) 2018-04-27 2020-11-24 Shionogi & Co Derivados de tetrahidropiranoxazina que tienen actividad inhibidora de beta-secretasa 1 (bace1) selectiva.
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (es) 1968-08-31 1970-03-03
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
KR100909918B1 (ko) 2003-05-20 2009-07-29 노파르티스 아게 과산화소체 증식체-활성화 수용체의 리간드로서의 ｎ-아실질소 헤테로환
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
ES2476605T3 (es) * 2007-04-24 2014-07-15 Shionogi & Co., Ltd. Derivados de aminohidrotiazina sustituidos con grupos cíclicos
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
EP2360155A4 (en) * 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
WO2010063718A1 (en) 2008-12-02 2010-06-10 ETH Zürich Screening assay for metabolic disease therapeuticals
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA110467C2 (uk) 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
CA2824493A1 (en) 2011-01-13 2012-07-19 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders
EP2665716B1 (en) 2011-01-21 2017-03-08 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
BR112013031098A2 (pt) 2011-06-07 2016-12-06 Hoffmann La Roche halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
KR20140041590A (ko) 2011-06-07 2014-04-04 에프. 호프만-라 로슈 아게 [1,3]옥사진

Also Published As

Publication number Publication date
EP3023423A1 (en) 2016-05-25
ES2638832T3 (es) 2017-10-24
SG2014012108A (en) 2014-05-29
EA201490491A1 (ru) 2014-06-30
KR20140054313A (ko) 2014-05-08
HK1195903A1 (en) 2014-11-28
AU2012298177A1 (en) 2014-03-06
EA024580B1 (ru) 2016-09-30
MX339303B (es) 2016-05-19
CL2014000458A1 (es) 2014-09-05
US20150150877A1 (en) 2015-06-04
TW201313706A (zh) 2013-04-01
ES2565229T3 (es) 2016-04-01
ZA201401139B (en) 2014-12-23
CN103906748A (zh) 2014-07-02
PL2748162T3 (pl) 2016-06-30
JP2014524463A (ja) 2014-09-22
MA35356B1 (fr) 2014-08-01
TN2014000062A1 (en) 2015-07-01
CN103906748B (zh) 2017-06-16
JP5816369B2 (ja) 2015-11-18
EP3023423B1 (en) 2017-05-31
AU2012298177B2 (en) 2015-10-29
GT201400031A (es) 2015-02-19
CR20140084A (es) 2014-05-02
AR087668A1 (es) 2014-04-09
AP2014007507A0 (en) 2014-03-31
BR112014004131A2 (pt) 2017-06-13
EP2748162B1 (en) 2015-12-16
IL230975A0 (en) 2014-03-31
EP2748162A1 (en) 2014-07-02
NZ621093A (en) 2015-05-29
KR101601571B1 (ko) 2016-03-08
WO2013027188A1 (en) 2013-02-28
US9163011B2 (en) 2015-10-20
US20130172331A1 (en) 2013-07-04
MX2014002230A (es) 2014-04-25
CA2845093A1 (en) 2013-02-28
CO6890097A2 (es) 2014-03-10
PE20141540A1 (es) 2014-10-31

Similar Documents

Publication Publication Date Title
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
UY33865A (es) Derivados Heterocíclicos Novedosos y su Uso en el Tratamiento de Trastornos Neurológicos
UY33946A (es) Derivados de c4-monometil triterpenoides y sus métodos de uso
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
UY33970A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
EA201500314A1 (ru) Лекарственные формы энзалутамида
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CO6950473A2 (es) Novedosos derivados de purina y su uso en el tratamiento de enfermedades
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY34539A (es) Heteroarilos y usos de los mismos
UY34018A (es) Derivados glucósidos y usos de los mismos
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020